Giovanni Palazzolo
Cittadella, 35013, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.
Journal: Journal of clinical medicine
Published: November 23, 2025
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study.
Journal: Cancer immunology, immunotherapy : CII
Published: March 09, 2025
Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer.
Journal: Expert opinion on biological therapy
Published: February 21, 2023
The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.
The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.
Journal: Current medicinal chemistry
Published: October 29, 2022
The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: June 21, 2022
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
Journal: The oncologist
Published: September 05, 2021
New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trials.
Journal: Expert opinion on investigational drugs
Published: July 10, 2020
Vascular endothelial growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small cell lung cancer.
Journal: Expert opinion on pharmacotherapy
Published: January 21, 2020
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).
Journal: The oncologist
Published: October 18, 2018
Treatment of advanced non-small cell lung cancer in the elderly.
Journal: Expert review of respiratory medicine
Published: August 11, 2018
J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
Journal: Journal of thoracic disease
Published: March 31, 2018
The safety of second-line treatment options for non-small cell lung cancer.
Journal: Expert opinion on drug safety
Published: March 10, 2017
Last Updated: 09/26/2026